BetterLife Pharma Inc., a publicly traded biotechnology company based in Vancouver, British Columbia, has announced the appointment of Dr. Mahan Chehrenama as its Chief Medical Officer. BetterLife focuses on developing innovative treatments aimed at neurological disorders, with a particular emphasis on creating non-hallucinogenic therapies. Dr. Chehrenama will be responsible for leading the clinical development of BETR-001, a medication that is progressing towards the submission of an Investigational New Drug application to regulatory authorities.
This appointment represents a significant step in the company’s strategy to enhance its leadership team as it strives to bring forward its neuroplastogen treatments. With a growing body of research spotlighting non-hallucinogenic solutions in the treatment of neurological conditions, BetterLife Pharma aims to make strides in this rapidly evolving field. The company’s commitment to driving clinical research and development is underscored by this leadership change, which may expedite the drug development process and strengthen its position in the biotech industry.
Analyzed Canadian Outlets (1)
1 headline